MedTrace Logo

Design of New Personalized Therapeutic Approaches for Diffuse Large B-cell Lymphoma

NCT03797170 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2023-02-08

No results posted yet for this study

Summary

In Europe diffuse large B-cell lymphoma (DLBCL) is a rare disease whereas in Italy it is not. Approximately 40% of DLBCL patients has refractory disease or will relapse after initial response. In onco-hematology, a role for gut microbiota (GM) in mediating immune activation in response to chemotherapy, has been suggested. In this scenario, the Investigators hypothesized that GM could play an important role in DLBCL prognosis and response to treatment, establishing a connection between lifestyle and clinical response. The project is aimed to the study of the functional GM layout in association with specific patterns of treatment response in de novo DLBCL undergoing standard first line chemo-immunotherapy. Results may build the scientific basis to design new and personalized intervention strategies (both in treatment approach and in life-style recommendations), to enhance clinical response and reduction of disease refractoriness through modulation of the gut microbial ecosystem.

Conditions

Interventions

OTHER

Gut microbiota samples

Gut microbiota analysis from diagnosis to follow up after first line-chemo-immuntherapy

Sponsors & Collaborators

  • University of Bologna

    lead OTHER

Principal Investigators

  • Pier Luigi L Zinzani, Professor · Institute of Hematology "L. e A. Seràgnoli", University of Bologna

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-04-02
Primary Completion
2023-07-20
Completion
2023-12-20

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03797170 on ClinicalTrials.gov